Buspirone Hydrochloride 30mg Tablets, Fasting

Phase 1 Completed 70 enrolled Teva Pharmaceuticals USA

RandomizedCrossoverOpen-labelOther

Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult volunteers under fasting conditions.

Timeline

Start: 2001-12
Primary completion: 2001-12
Completion: 2002-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buspirone	Small molecule	30 mg	Oral

Indications

No indication recorded.